Hyun Joo Jang

Hyun Joo Jang


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 June 2016 in Oncotarget
Verified
Journal Article
Open access
HJHyun Joo Jang
Hyun Joo Jang
EHEun Mi Hong
Eun Mi Hong
MKMikang Kim
Mikang Kim
JKJae Hyun Kim
Jae Hyun Kim
JJJuah Jang
Juah Jang
JLJin Lee
Jin Lee
Simvastatin induces heme oxygenase-1 via NF-E2-related factor 2 (Nrf2) activation through ERK and PI3K/Akt pathway in colon cancer

9 October 2018 in Gastroenterology Research and Practice
Verified
Journal Article
Open access
PDF file
BKBum Jun Kim
Bum Jun Kim
HKHyeong Su Kim
Hyeong Su Kim
HJHyun Joo Jang
Hyun Joo Jang
JKJung Han Kim
Jung Han Kim
Objective.Several recent reviews of published studies have shown that the eradication ofH. pyloriinfection in patients with ITP improved thrombocytopenia in about half of the cases. However, most included studies were observational case series. We performed the first meta-analysis of randomized trials to gain a better insight into the effect ofH. pylorieradication in ITP patients.Methods.A systematic computerized search of the electronic databases including PubMed, EMBASE, Google Scholar, and Cochrane Library (up to December 2017) was conducted.Results.From six studies, a total of 241 patients (125 in eradication group and 116 in control group) were included in the meta-analysis. Patients in the eradication group showed significantly higher overall platelet response rate than those in the control group (odds ratio = 1.93, 95% confidence interval: 1.01–3.71,P=0.05). In the subgroup analysis, however, children in the eradication group failed to show statistically better response rate than those in the noneradication group (odds ratio = 1.80, 95% confidence interval: 0.88–3.65,P=0.11).Conclusions.This meta-analysis indicates thatH. pylorieradication has a significant therapeutic effect in patients with ITP. Considering the intrinsic limits in the design and sample size of the included studies, however, large randomized controlled trials are warranted to validate the therapeutic impact ofH. pylorieradication in adults as well as children with ITP.

1 January 2019 in Journal of Cancer
Verified
Journal Article
Open access
HKHyeong Su Kim
Hyeong Su Kim
JKJung Han Kim
Jung Han Kim
HJHyun Joo Jang
Hyun Joo Jang
BHBoram Han
Boram Han
DZDae Young Zang
Dae Young Zang
Fibroblast growth factor receptor-2 (FGFR2) protein expression by immunohistochemistry has been reported in up to 60% of patients with gastric cancer (GC). However, the clicopathological impacts of high FGFR2 expression have not been consistent among studies. We conducted this meta-analysis to evaluate the pathological and prognostic significance of FGFR2 overexpression in patients with GC. A systematic search of the electronic databases including PubMed, PMC, EMBASE, and Google Scholar was performed. From ten studies, 4,294 patients were included in the pooled analyses of odds ratios (ORs) with 95% confidence intervals (CIs) for pathological features and hazard ratios (HRs) with 95% CIs for overall survival according to the FGFR2 expression status. Compared with tumors showing low FGFR2 expression, GCs with FGFR2 overexpression revealed deeper depth of invasion (pT3-4) (OR = 2.63, 95% CI: 1.70-4.06, p < 0.0001), higher rate of lymph node metastasis (OR = 1.87, 95% CI: 1.31-2.67, p < 0.0001), and more advanced stage (III-IV) (OR = 1.78, 95% CI: 1.07-2.96, p = 0.03). In addition, patients with FGFR2-overexpressed GC showed significantly worse survival than those with FGFR2-low tumor (HR = 1.40, 95% CI: 1.25-1.58, p < 0.00001). In conclusion, this meta-analysis indicates that FGFR2 overexpression is associated with poor pathological features and prognosis in patients with GC.

31 December 2020 in Gut and Liver
Verified
Journal Article
Open access
PDF file
EJEun Suk Jung
Eun Suk Jung
SLSang Pyo Lee
Sang Pyo Lee
SKSea Hyub Kae
Sea Hyub Kae
JKJung Han Kim
Jung Han Kim
HKHyeong Su Kim
Hyeong Su Kim
HJHyun Joo Jang
Hyun Joo Jang
Eun Suk Jung, Sang Pyo Lee, Sea Hyub Kae, Jung Han Kim, Hyeong Su Kim, and Hyun Joo Jang. Gut and Liver 2021;15:732-41. https://doi.org/10.5009/gnl20249

13 May 2016 in Oncology Letters
Verified
Journal Article
Open access
PDF file
HJHyun Joo Jang
Hyun Joo Jang
EHEun Mi Hong
Eun Mi Hong
SPSe Woo Park
Se Woo Park
HBHyun Woo Byun
Hyun Woo Byun
DKDong Hee Koh
Dong Hee Koh
JLJin Lee
Jin Lee
Insulin-like growth factor 1 (IGF-1) and IGF-1 receptor (IGF-1R) signaling plays an important role in tumor progression in patients with certain gastrointestinal tract cancers. In addition to lowering cholesterol in serum, statins have pleiotropic effects, including anti-oxidative, anti-inflammatory or anti-neoplastic effects. Therefore, the present study investigated whether statins could induce the apoptosis of colon cancer cells and regulate the expression of IGF-1R and its associated signaling pathways in the present study. It was demonstrated that simvastatin and pravastatin suppressed cell proliferation and induced cell death in human HT-29 cells, but simvastatin was more potent than pravastatin. Simvastatin induced apoptosis in a concentration-dependent manner. In addition, simvastatin suppressed the expression of IGF-1R and inhibited the activity of phosphorylated-extracellular signal-regulated kinase (ERK)1/2 and phosphorylated-Akt activated by IGF-1. Simvastatin and IGF-1 each stimulated the activity of phosphorylated ERK1/2. However, simvastatin inhibited cell proliferation and IGF-1 stimulated cell proliferation. Mevalonic acid and PD98059 reversed the ERK activation and apoptosis induced by treatment with simvastatin. It was concluded that simvastatin induces the apoptosis of human colon cancer cells and inhibits IGF-1-induced ERK and Akt expression via the downregulation of IGF-1R expression and proapoptotic ERK activation. Simvastatin may be beneficial for the treatment of colon cancer. The present study suggested that statin may possess therapeutic potential for the treatment of colon cancer.

9 August 2017 in Oncotarget
Verified
Journal Article
Open access
PDF file
JKJung Han Kim
Jung Han Kim
HKHyeong Su Kim
Hyeong Su Kim
BKBum Jun Kim
Bum Jun Kim
HJHyun Joo Jang
Hyun Joo Jang
JLJin Lee
Jin Lee
Prognostic value of c-Met overexpression in hepatocellular carcinoma: a meta-analysis and review Prognostic value of c-Met overexpression in hepatocellular carcinoma: a meta-analysis and review